Search Results 1111-1120 of 17100 for monoclonal antibody

1. A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine - Mayo Clinic

   Treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the CGRP pathway.

2. Muscle pain - Mayo Clinic

   Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · Muscle cramp · Muscle strains · Myalgic ...

3. Anand Padmanabhan, M.B.B.S., Ph.D. - Doctors and Medical Staff - Mayo Clinic

   ... (monoclonal gammopathy of thrombotic/thrombocytopenic significance). ... MemberThe Antibody Society. 2021 - present. FacultyDLMP Research Strategy: Mentoring ...

4. A Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma - Mayo Clinic

   ... antibody. - Refractory to, or had documented ... * Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome * ...

5. A Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection - Mayo Clinic

   Bezlotoxumab (CDI monoclonal antibodies) if received within the last year. Disease symptoms (diarrhea) caused by a confirmed intestinal pathogen other than ...

6. Cross-Variant Memory B Cell and T Cell Responses After COVID-19 mRNA Vaccine Booster - Mayo Clinic

   Receipt of any COVID-19-specific monoclonal antibodies within the past 90 days prior to enrollment. Any acute illness within the last 30 days. Blood ...

7. Cancer - Care at Mayo Clinic

   Monoclonal antibody drugs · Mort Crim and Cancer · Mouth sores caused by cancer treatment: How to cope · Myths about cancer causes · No appetite? How to get ...

8. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors - Mayo Clinic

   Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: ≤4 weeks (≤3 weeks with documented disease ...

9. A Study of KRN23 in Adult Subjects with Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome - Mayo Clinic

   Have used a therapeutic monoclonal antibody, including KRN23, within 90 days prior to Screening or have a history of allergic or anaphylactic reactions to any ...

10. Mayo-Adimune Collaborative and Programmatic Approach to Tolerization Therapy - Mayo Clinic

    The purpose of this study is to target two autoimmune neurological conditions that we consider proof of principal T cell- and antibody ... antibody titer greater ...